Skip to content

Study · Randomized controlled trial · n = 24 · 2026

8 results

Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial.

Pasqua MR, Doumat J, Tsoukas MA, Haidar A

Canadian journal of diabetes30 Oct 2025Cited by 1 (Europe PMC)

PMID41175929 (opens in a new tab)DOI10.1016/j.jcjd.2025.10.175 (opens in a new tab)PepBankPUB-41175929
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes, 42% of interviewed patients were interested in using semaglutide outside the study, citing lower insulin needs, weight loss and better glycemic management.

    In plain wordsIn adults with type 1 diabetes, 42% of those interviewed wanted to keep using semaglutide, citing less insulin, weight loss and better glucose control.

    Peptide
    Semaglutide
    Outcome
    Not applicableInterest in semaglutide use outside the study (interviews)
    Study

    n = 24

    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Measurements

    Patients interested in semaglutide use
    42%
    interviews

    Source sentences

    Summary
    Within the interviews, 42% of patients expressed interest in semaglutide use outside the study, with their reasons being lower insulin requirements, weight loss, and improved glycemic management.
    1 context sentence
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.
  2. 02HumanRandomized controlled trialSafety outcome

    In adults with type 1 diabetes, interviews reported that nausea and fear of vomiting hindered accurate carbohydrate estimation and pre-meal bolus dosing during semaglutide use.

    In plain wordsIn adults with type 1 diabetes, interviewees said nausea and fear of vomiting made it hard to work out pre-meal insulin doses on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableNausea and fear of vomiting as barriers to preprandial bolus
    Study

    n = 24

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Source sentences

    Summary
    Nausea and fear of vomiting were barriers to accurate preprandial determination of upcoming carbohydrate intake and thus preprandial bolus.
    1 context sentence
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes, interviewed participants noted synergy between semaglutide and automated insulin delivery.

    In plain wordsIn adults with type 1 diabetes, interviewed participants said semaglutide and their automated insulin system worked well together.

    Peptide
    Semaglutide
    Outcome
    Not applicableSynergy between semaglutide and automated insulin delivery (interviews)
    Study

    n = 24

    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Source sentences

    Summary
    Synergy was noted between the drug and automated insulin delivery by the participants.
    1 context sentence
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with type 1 diabetes using automated insulin delivery, semaglutide increased bowel symptom frequency and severity on the DBSQ versus placebo.

    In plain wordsIn adults with type 1 diabetes, semaglutide caused more frequent and more severe bowel symptoms than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiabetes Bowel Symptom Questionnaire score
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Source sentences

    Summary
    For semaglutide vs placebo, only the DBSQ showed differing scores with increased symptom frequency and severity with semaglutide.
    1 context sentence
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes using automated insulin delivery, Diabetes Distress Scale scores did not differ between semaglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, diabetes distress scores were not different between semaglutide and placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiabetes Distress Scale score
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Source sentences

    Summary
    For semaglutide vs placebo, only the DBSQ showed differing scores with increased symptom frequency and severity with semaglutide.
    2 context sentences
    Summary · context
    The following questionnaires were used after each intervention: the Diabetes Distress Scale; the Hypoglycemia Fear Survey; the Diabetes Treatment Satisfaction Questionnaire; Insulin-delivery Systems: Perceptions, Ideas, Reflections and Expectations (INSPIRE); and the Diabetes Bowel Symptom Questionnaire (DBSQ).
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes using automated insulin delivery, Hypoglycemia Fear Survey scores did not differ between semaglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, fear of low blood sugar scores were not different between semaglutide and placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypoglycemia Fear Survey score
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Source sentences

    Summary
    For semaglutide vs placebo, only the DBSQ showed differing scores with increased symptom frequency and severity with semaglutide.
    2 context sentences
    Summary · context
    The following questionnaires were used after each intervention: the Diabetes Distress Scale; the Hypoglycemia Fear Survey; the Diabetes Treatment Satisfaction Questionnaire; Insulin-delivery Systems: Perceptions, Ideas, Reflections and Expectations (INSPIRE); and the Diabetes Bowel Symptom Questionnaire (DBSQ).
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes using automated insulin delivery, treatment satisfaction scores did not differ between semaglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, treatment satisfaction scores were not different between semaglutide and placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiabetes Treatment Satisfaction Questionnaire score
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Source sentences

    Summary
    For semaglutide vs placebo, only the DBSQ showed differing scores with increased symptom frequency and severity with semaglutide.
    2 context sentences
    Summary · context
    The following questionnaires were used after each intervention: the Diabetes Distress Scale; the Hypoglycemia Fear Survey; the Diabetes Treatment Satisfaction Questionnaire; Insulin-delivery Systems: Perceptions, Ideas, Reflections and Expectations (INSPIRE); and the Diabetes Bowel Symptom Questionnaire (DBSQ).
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes using automated insulin delivery, INSPIRE scores did not differ between semaglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, scores on views about insulin-delivery systems were not different between semaglutide and placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeINSPIRE score
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · 15 weeksAs given in this study (human).

    Source sentences

    Summary
    For semaglutide vs placebo, only the DBSQ showed differing scores with increased symptom frequency and severity with semaglutide.
    2 context sentences
    Summary · context
    The following questionnaires were used after each intervention: the Diabetes Distress Scale; the Hypoglycemia Fear Survey; the Diabetes Treatment Satisfaction Questionnaire; Insulin-delivery Systems: Perceptions, Ideas, Reflections and Expectations (INSPIRE); and the Diabetes Bowel Symptom Questionnaire (DBSQ).
    Summary · context
    This work is an analysis from a double-blind, randomized, crossover trial assessing semaglutide vs placebo, with automated insulin delivery in adults with type 1 diabetes, after 15-week interventions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.